Table 2. Comparison of the laboratory parameters of patients according to the periods of extracorporeal hemadsorption.
aP<0.05 vs pre-HAD IL-6. bP<0.05 vs pre-HAD IL-8. cP<0.05 vs pre-HAD IL-10. dP<0.05 vs pre-HAD TNF-α. eP<0.05 vs pre-HAD PCT. fP<0.05 vs pre-HAD CRP
SD: standard deviation; HAD: hemadsorption; IL: interleukin; TNFα: tumor necrosis factor α; PCT: procalcitonin; CRP: C-reactive protein; APACHE: Acute Physiology and Chronic Health Evaluation; PMR: predicted mortality rate of the study population calculated based on APACHE score; SOFA: Sequential Organ Failure Assessment
| Parameter | Period | Mean ± SD; median (range) | P-value |
| IL-6 (ng/L) | Pre-HAD | 129.32 ± 41.24; 115.05 (54.3–225.8) | 0.001 |
| Intra-HAD | 101.7 ± 36.3a; 89.1 (47.2–177.4) | ||
| Post-HAD | 88.35 ± 55.01a; 84.7 (5.7–206.4) | ||
| IL-8 (ng/L) | Pre-HAD | 86.14 ± 58.34; 81.85 (7.87–215.4) | 0.0001 |
| Intra-HAD | 52.76 ± 47.98; 45.46 (0.14–158.2) | ||
| Post-HAD | 38.37 ± 40.36b; 24.51 (1.24–154.3) | ||
| IL-10 (ng/L) | Pre-HAD | 172.33 ± 187.72; 117.2 (23.15–856.3) | 0.0001 |
| Intra-HAD | 115.77 ± 88.89c; 93.95 (14.9–389.2) | ||
| Post-HAD | 82.8 ± 61.34c; 69.7 (0.15–292.2) | ||
| TNFα (pg/mL) | Pre-HAD | 86.85 ± 49.9; 71.65 (12.45–212.2) | 0.0001 |
| Intra-HAD | 52.61 ± 34.44d; 48.5 (3.24–151.5) | ||
| Post-HAD | 22.64 ± 20.37d; 14.6 (1.23–98.2) | ||
| PCT (ng/mL) | Pre-HAD | 6.74 ± 11.09; 2.17 (0.28–57) | 0.001 |
| Intra-HAD | 2.24 ± 3e; 0.95 (0.1–15) | ||
| Post-HAD | 2.2 ± 3.15e; 0.61 (0.06–4) | ||
| CRP (mg/mL) | Pre-HAD | 183.75 ± 70; 176 (63–350) | 0.0001 |
| Intra-HAD | 121.38 ± 57.71f; 108.5 (37–259) | ||
| Post-HAD | 97.57 ± 70.21f; 83 (9.2–338) | ||
| APACHE score | Pre-HAD | 33.94 ± 9.71; 35.5 (13–50) | 0.001 |
| Post-HAD | 26.94 ± 9.47; 26.5 (8–47) | ||
| PMR | Pre-HAD | 73.76 ± 22.81; 80.02 (16.54–98.01) | 0.001 |
| Post-HAD | 58.94 ± 21.99; 55.47 (11.34–96.53) | ||
| SOFA score | Pre-HAD | 16.06 ± 3.08; 16 (10–24) | 0.0001 |
| Post-HAD | 12.48 ± 3.79; 12 (5–21) |